San Diego-based mostly Viking Therapeutics marked itself as a serious competitor from the weight loss drug marketplace in February after revealing promising data from the mid-phase trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when p